EUVIMEDEUVIMED entdecken
Fallbericht

Eculizumab as first-line treatment for patients with severe presentation of complement factor H antibody–mediated hemolytic uremic syndrome

Paula A Coccia, Laura F Alconcher, Veronica Ferraris, Lucas I Lucarelli, Maria A Grillo, Maria Andrea Arias, Mariana Saurit, Viviana M Ratto, Celia Dos Santos, Analía Sánchez-Luceros

Pediatric Nephrology · 2025

DOI: 10.1007/s00467-024-06530-2 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Pediatric Nephrology, 2025. Verfasst von Paula A Coccia und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pediatric Nephrology, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina. paula.coccia@hospitalitaliano.org.ar. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Hemolytic-Uremic Syndrome, Complement Factor H, Immunosuppressive Agents. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 22 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Complement factor H (FH) antibody-mediated hemolytic uremic syndrome (HUS) has varying prevalence globally. Plasmapheresis and immunosuppressive drugs are the standard treatment. Recently, eculizumab has been reported as an effective alternative. This study aims to report four children with FH antibody-mediated HUS managed with eculizumab plus immunosuppression as first-line therapy. METHODS: A retrospective chart review was conducted for children aged ≤ 18 years old with complement-mediated HUS in two referral centers. Patients with FH antibody-mediated HUS treated with eculizumab as first-line therapy were included. RESULTS: Four children (aged 6-11 years old) were included. Dialysis was necessary in three patients. Eculizumab was administered 5-23 days after onset. None of them received plasmapheresis. Prednisone and mycophenolate mofetil were added after receiving positive FH antibody results. Hematological signs and kidney function improved after the second eculizumab dose. Eculizumab was discontinued in three patients after 6 months. One patient required rituximab due to persistent high FH antibody titers; discontinuation of eculizumab occurred after 15 months without recurrence. No treatment-related complications were observed. During a mean 12-month follow-up (range 6-24 months), no relapses were recorded and all patients ended with normal GFR. CONCLUSION: Our data suggest that a short course of 6 months of C5 inhibitor might be sufficient to reverse thrombotic microangiopathy symptoms and improve kidney function in patients with severe FH antibody-mediated HUS. Simultaneously, adding immunosuppressive agents might reduce the risk of relapse and allow cessation of C5 inhibition in a shorter period of time.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedHemolytic-Uremic SyndromeComplement Factor HImmunosuppressive AgentsHumansChildMaleRetrospective StudiesFemaleTreatment OutcomeRenal DialysisComplement Inactivating Agents

Stichwörter der Autor:innen

Anti-factor H antibodiesAtypical HUSComplement factor HComplement-mediated HUSEculizumabThrombotic microangiopathy

Substanzen

eculizumabAntibodies, Monoclonal, HumanizedComplement Factor HImmunosuppressive AgentsComplement Inactivating Agents

Autor:innen und Institutionen

  • Division of Pediatric Nephrology, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina. paula.coccia@hospitalitaliano.org.ar.
  • Pediatric Nephrology Unit, Hospital Interzonal General Dr. José Penna, Bahía Blanca, Buenos Aires, Argentina.
  • Division of Pediatric Nephrology, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.
  • Department of Pediatric Nephrology, Hospital Materno Infantil Dr. Héctor Quintana Jujuy, San Salvador de Jujuy, Argentina.
  • Pediatric Nephrology, Department Hospital Materno Infantil, Salta, Argentina.
  • Pediatric Department, Fundacion Hospitalaria, Buenos Aires, Argentina.

Zitieren

APA

Coccia, P. A., Alconcher, L. F., Ferraris, V., Lucarelli, L. I., Grillo, M. A., Arias, M. A., Saurit, M., Ratto, V. M., Dos Santos, C., & Sánchez-Luceros, A. (2025). Eculizumab as first-line treatment for patients with severe presentation of complement factor H antibody–mediated hemolytic uremic syndrome. Pediatric Nephrology. https://doi.org/10.1007/s00467-024-06530-2

Vancouver

Coccia PA, Alconcher LF, Ferraris V, Lucarelli LI, Grillo MA, Arias MA, et al. Eculizumab as first-line treatment for patients with severe presentation of complement factor H antibody–mediated hemolytic uremic syndrome. Pediatric Nephrology. 2025. doi:10.1007/s00467-024-06530-2

BibTeX
@article{Coccia2025,
  author = {Coccia, Paula A and Alconcher, Laura F and Ferraris, Veronica and Lucarelli, Lucas I and Grillo, Maria A and Arias, Maria Andrea and Saurit, Mariana and Ratto, Viviana M and Dos Santos, Celia and Sánchez-Luceros, Analía},
  title = {Eculizumab as first-line treatment for patients with severe presentation of complement factor H antibody–mediated hemolytic uremic syndrome},
  journal = {Pediatric Nephrology},
  year = {2025},
  doi = {10.1007/s00467-024-06530-2}
}
Kostenlos starten →